Therapeutic Or Pharmaceutical Composition Patents (Class 977/915)
-
Patent number: 8357845Abstract: A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca2+ into mitochondria is provided, including administering a pharmaceutically effective amount of nanotubes into the subject. A method of reducing weight, treating cancer, reducing the effects of traumatic brain injury, or reducing the effects of ageing, in a subject including administering a pharmaceutically effective amount of nanotubes into the subject is also provided.Type: GrantFiled: February 25, 2011Date of Patent: January 22, 2013Assignee: University of Kentucky Research FoundationInventor: Patrick G. Sullivan
-
Patent number: 8357374Abstract: The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.Type: GrantFiled: February 7, 2008Date of Patent: January 22, 2013Assignee: The Regents of the University of CaliforniaInventors: Dennis A. Carson, Wolfgang Wrasidlo, Christina C. N. Wu
-
Publication number: 20130011333Abstract: The present invention provides methods and compositions to selectively and directly deliver nanoparticles carrying an active agent to tumor cells. The active agent is internalized by the tumor cells, producing an anti-tumor effect for therapeutic applications and/or depositing a detectable marker for diagnostic applications. The present invention further provides a p53 chimera that circumvents the dominant negative activity of mutant p53 as a therapeutic in the treatment of cancer and reduction of mor size.Type: ApplicationFiled: January 18, 2011Publication date: January 10, 2013Applicant: Board of Regents, The University of Texas SystemInventors: Zhi-Min Yuan, Seog-Jin Seo
-
Publication number: 20130011457Abstract: Biodegradable cationic block copolymers are disclosed, comprising a hydrophilic block comprising first repeat units derived from a first cyclic carbonyl monomer by ring-opening polymerization, wherein more than 0% of the first repeat units comprise a side chain moiety comprising a quaternary amine group; a hydrophobic block comprising second repeat units derived from a second cyclic carbonyl monomer by ring-opening polymerization; an optional endcap group; and a chain fragment derived from an initiator for the ring opening polymerization. The cationic block copolymers form aqueous micelle mixtures suitable for antimicrobial applications.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: James Hedrick, Kazuki Fukushima, Yi Yan Yang
-
Publication number: 20130006092Abstract: The present invention relates to diagnosis and treatment of medical conditions using magnetic nanoparticle compositions.Type: ApplicationFiled: June 17, 2012Publication date: January 3, 2013Applicant: NANOVORTEX LLCInventors: Richard Ferrans, Mridula Pottathil Sherin, Raveendran Pottathil
-
Publication number: 20130006038Abstract: A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells. In one embodiment, the method provides a synergistic effect with chemotherapy.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Inventor: Gholam A. Peyman
-
Publication number: 20130004557Abstract: Methods for making antimicrobial resins and for forming coatings comprising antimicrobial resins on substrate surfaces are disclosed. The methods involve providing a mixture comprising about 15 weight % to about 80 weight % of a hydrophilic acrylic oligomer, about 10 weight % to about 80 weight % of a multifunctional acrylic monomer, about 5 weight % to about 40 weight % of an adhesion-promoting acrylic or vinyl monomer, and about 0.1 weight % to about 15 weight % of a metal salt; and exposing the mixture to a radiation source to cure at least a portion of the mixture, thereby forming an antimicrobial resin.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Applicants: BAXTER INTERNATIONAL INC.Inventors: Vadim V. Krongauz, Dustin C. Cawthon, Michael Tung-Kiung Ling
-
Publication number: 20130004417Abstract: The present invention is directed ?-particle emitting nanoparticles that comprise a lanthanide phosphate sequestration shell enclosing an ?-emitting-radioisotope-doped lanthanide phosphate core such that the shell allows at least some of the ? emissions from the ?-emitting radioisotope to pass therethrough and prevents at least some radioactive decay products of the ?-emitting radioisotope from exiting the ?-particle emitting nanoparticle. Further, such ?-particle emitting nanoparticles may be coated with gold and functionalized. Additionally, a method for making and using the same are disclosed.Type: ApplicationFiled: January 3, 2012Publication date: January 3, 2013Applicant: THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: John David Robertson, Mark F. McLaughlin, Paul H. Pevsner
-
Publication number: 20130004584Abstract: The present invention provides cerium oxide nanoparticles for use both in therapeutic compositions in vivo and in research in vitro. The cerium oxide nanoparticles are of known range of sizes having biological properties that are reproducible and beneficial. Pharmaceutical and other compositions are provided, as are methods of treatment.Type: ApplicationFiled: July 2, 2012Publication date: January 3, 2013Inventors: Beverly A. Rzigalinski, Ariane M. Clark
-
Publication number: 20120328665Abstract: Disclosed herein are a composite nanoparticle and a process for preparing the same. The composite nanoparticle includes Rev peptides chemically bonded to gold. Also disclosed herein are a pharmaceutical composition including a plurality of the aforesaid composite nanoparticles, and a method of inhibiting tumor/cancer cells by virtue of the aforesaid composite nanoparticle.Type: ApplicationFiled: July 22, 2011Publication date: December 27, 2012Applicant: National Taiwan University of Science and TechnologyInventors: Yian Tai, Yat Ming Yung, Tzu-Hao Wang, Tran Thi Thanh Ngoc
-
Publication number: 20120329708Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.Type: ApplicationFiled: June 12, 2012Publication date: December 27, 2012Applicant: Indiana University Research and Technology CorporationInventors: Richard D. DiMARCHI, David L. SMILEY
-
Publication number: 20120328538Abstract: The present disclosure describes a replacement for petroleum jelly as a base for products which is suitable for most any application for which petroleum jelly can be used. The jelly is a glycerine based jelly composition comprising; vegetable derived glycerine and an emulsifier, wherein the emulsifier can be any known and/or commercially available glucoside containing emulsifier. Other suitable emulsifiers together with glycerine and essential or vegetable based oils with or without inorganic fillers may also be added to the jelly to impart fragrance, color, UVA and UVB sun protection factor(s), immuno-enhancing aromatherapeutics, as well as free radical scavenging constituents. In addition, temperature stabilizers and stiffening agents such as waxes and other inorganic fillers including silica and clays may also be added during manufacture as required. The glycerine is preferably present in the range of 50-95%.Type: ApplicationFiled: December 9, 2010Publication date: December 27, 2012Inventors: Guerry L. Grune, William Wingfield
-
Publication number: 20120329707Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.Type: ApplicationFiled: June 12, 2012Publication date: December 27, 2012Applicant: Indiana University Research and Technology CorporationInventors: Richard D. DiMARCHI, David L. SMILEY, Bin YANG
-
Publication number: 20120328681Abstract: The present invention relates to protecting a human from an infection using a disinfecting agent as described herein and a method for use thereof, more particularly to a rare earth-containing device for protecting a wound and a method for use thereof.Type: ApplicationFiled: September 10, 2012Publication date: December 27, 2012Applicant: MOLYCORP MINERALS, LLCInventors: Carl R. Hassler, John L. Burba, Charles Whitehead, Joe Pascoe
-
Publication number: 20120328701Abstract: The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof.Type: ApplicationFiled: January 23, 2012Publication date: December 27, 2012Applicant: ANTERIOS, INC.Inventors: Jonathan EDELSON, Timothy KOTYLA, Klaus THEOBALD
-
Publication number: 20120322884Abstract: The invention provides a composition including epinephrine nanoparticles and methods for therapeutic use of the composition in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.Type: ApplicationFiled: March 1, 2011Publication date: December 20, 2012Applicants: UNIVERSITY OF MANITOBA, NOVA SOUTHEASTERN UNIVERSITYInventors: Mutasem Rawas-Qalaji, Enrique Nieves, Keith John Simons, Frances Estelle Reed Simons, Ousama Rachid
-
Publication number: 20120322739Abstract: The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin.Type: ApplicationFiled: May 4, 2012Publication date: December 20, 2012Applicants: Novozymes Biopharma UK Limited, Novozymes Biopharma DK A/S, Novozymes A/S, University of OsloInventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Delahay
-
Publication number: 20120315480Abstract: The present invention relates to thiol- or an amine-associated ferromagnetic or superparamagnetic copper nanoparticles with an average diameter less than 30 nm, to the method for obtaining them and their applications in biomedicine and other fields.Type: ApplicationFiled: July 31, 2009Publication date: December 13, 2012Applicant: UNIVERSIDAD DEL PAIS VASCOInventors: José Javier Saiz Garitaonandia, Eider Goikolea Núñez, Teófilo Rojo Aparicio, Maite Insausti Peña, Fernando Plazaola Muguruza
-
Publication number: 20120315306Abstract: A pharmaceutical composition including drug-containing nanoparticles having an average particle diameter of from 10 nm to 150 nm, the pharmaceutical composition being obtained by mixing water with a poorly water soluble drug-containing, water miscible solution that contains a poorly water soluble drug having a water solubility of 50 ?g/mL or less, a water soluble copolymer having a repeating unit represented by the following Formula (1), and a water miscible miscible solvent, wherein in Formula (1), n:m is within a range of from 0.25:0.75 to 0.95:0.05, R represents an alkyl group which may have a substituent, R1 and R2 each independently represent a hydrogen atom or a methyl group, and Me represents a methyl group; and a preparation for oral administration, which includes the pharmaceutical composition.Type: ApplicationFiled: January 27, 2011Publication date: December 13, 2012Applicant: FUJIFILM CORPORATIONInventor: Shigetomo Tsujihata
-
Publication number: 20120315336Abstract: Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine.Type: ApplicationFiled: May 3, 2012Publication date: December 13, 2012Applicant: Alkermes Pharma Ireland LimitedInventors: Stephen B. Ruddy, David Czekai, Gary Liversidge, Scott A. Jenkins, Elaine M. Liversidge
-
Publication number: 20120315320Abstract: Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof.Type: ApplicationFiled: January 6, 2012Publication date: December 13, 2012Inventors: Paul J. Davis, Shaker A. Mousa
-
Publication number: 20120308616Abstract: A submicron emulsion of paclitaxel, the preparation method and the use thereof are disclosed. Said paclitaxel submicron emulsion comprises paclitaxel/steroid complex, oil for injection, water for injection, emulsifier, assistant emulsifier and isotonic agent, wherein the mole ratio of paclitaxel to steroid in the complex is 1:0.2Ëś4; preferably 1:0.25Ëś2. Said submicron emulsion is useful for the treatment for malignant tumor. The average particle diameter of the submicron emulsion is less than 400 nm and the pH Value is 3.5-6.Type: ApplicationFiled: October 28, 2010Publication date: December 6, 2012Applicant: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Yuling Liu, Xuejun Xia, Ruifang Guo, Pengxiao Zhang, Rui Han, Zhaodi Fu, Cuiping Zhou, Renyun Wang, Dujia Jin
-
Publication number: 20120308548Abstract: The invention relates to a methionine gamma lyase-2-aminobutyrate deaminase (MEGL-2ABD) enzyme and provides an isotopic assay for quantitatively measuring activity of the enzyme. The MEGL-2ABD is a therapeutic target for cancer, particularly in cancer stem cells and their lineages. The invention additionally provides a protein, MEGL-2ABD (SEQ ID NO:2), compositions/formulations containing this protein, and methods/assays for using this protein in therapeutic applications allowing progress toward prevention, diagnosis, treatment, and cure of cancer.Type: ApplicationFiled: February 10, 2011Publication date: December 6, 2012Applicant: NOVA SOUTHEASTERN UNIVERSITYInventor: Kallidaikurichi V. Venkatachalam
-
Publication number: 20120308612Abstract: The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions, for example upon dilution for administration.Type: ApplicationFiled: February 29, 2012Publication date: December 6, 2012Inventors: Tapas DE, Neil P. DESAI, Andrew YANG, Zachary YIM, Patrick SOON-SHIONG
-
Publication number: 20120308662Abstract: The present invention aims to provide a particulate formulation with an effectively controlled dissolution characteristic of a drug even if the average particle diameter is small. The present invention provides a particulate formulation containing drug particles and a first coating layer coating the drug particles and characterized in that the first coating layer contains a water-insoluble polymer, inorganic particles, and/or a lipid component and the lipid component contains a C15 or higher fatty acid.Type: ApplicationFiled: May 30, 2012Publication date: December 6, 2012Applicant: NITTO DENKO CORPORATIONInventors: Tatsuya KONISHI, Daisuke ASARI, Takuya SHISHIDO, Arimichi OKAZAKI, Mitsuhiko HORI
-
Publication number: 20120308657Abstract: The present invention relates to magnetic nanostructures as theranostic agents, which provide dual function as diagnostic and therapeutic agents. In particular, the present invention relates to compositions comprising magnetic nanostructures and their use as targeted therapeutic agents for cancers (e.g., medulloblastoma) and Alzheimer's disease and related diseases and conditions.Type: ApplicationFiled: November 1, 2010Publication date: December 6, 2012Applicant: NORTHWESTERN UNIVERSITYInventors: Vinayak P. Dravid, Saurabh Sharma, Tadanori Tomita, Kirsten L. Viola, William L. Klein
-
Publication number: 20120308623Abstract: The present invention is directed to a composition comprising nanoparticles of TiO2 having a mean particle diameter (D50) of about 20-50 nm at a concentration of about 1-2000 g/L and H2O2 at a final concentration at about 2.5-25% by volume. The TiO2 particles are activated by the H2O2 in the composition to form radicals. The composition has antimicrobial and anti-inflammatory properties and may be used for e.g. wound debridement. The invention further concerns medical and cosmetic products and devices comprising the composition.Type: ApplicationFiled: December 15, 2010Publication date: December 6, 2012Inventors: Sebastien Francis Michel Taxt-Lamolle, S. Petter Lyngstadaas, Havard J. Haugen
-
Publication number: 20120308614Abstract: The present invention relates to a novel aqueous liquid pharmaceutical composition for the controlled release of buprenorphine or of an analogue of buprenorphine, comprising at least one prodrug with low aqueous solubility of said buprenorphine or analogue of buprenorphine, and at least one polymer having a linear backbone chosen from the polyglutamates, polyaspartates, poly(meth)acrylates and polysaccharides, to which one or more hydrophobic groups are grafted.Type: ApplicationFiled: May 30, 2012Publication date: December 6, 2012Applicant: Flamel TechnologiesInventors: Aline Moulin, You-Ping Chan
-
Patent number: 8323698Abstract: The present invention generally relates to polymers and macromolecules, in particular, to block polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. The moiety, in some embodiments, may have a molecular weight greater than about 1000 Da; for example, the moiety may include a polypeptide or a polynucleotide, such as an aptamer. The moiety may also be a targeting moiety, an imaging moiety, a chelating moiety, a charged moiety, or a therapeutic moiety.Type: GrantFiled: September 1, 2010Date of Patent: December 4, 2012Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.Inventors: Frank X. Gu, Omid C. Farokhzad, Robert S. Langer, Benjamin A. Teply
-
Publication number: 20120301487Abstract: A process for substantially reducing levels of circulating chromatin fragments (CCFs) from a medium using binding agents such as antibodies or antibodies complexed with haemocompatible natural polymer substrates like as alginates, chitosan and pullulan to form complexed antibody-substrate nano-particulates (CNP) to bind and/or inactivate CCFs is disclosed. The amount of antibody bound to the polymer varies from 30% to 100% of activated sites in the polymer. Elevated levels of CCFs can be substantially reduced following administration of tissue damaging agents that generate apoptotic chromatin fragments by the concomitant administration of CNPs or concomitant administration of H4 antibody alone. A method of treatment is disclosed wherein therapeutic dose of CNPs, or H4 antibody alone, are administered systematically, or orally, in a delivery system to curb pathological conditions that are associated with increased burden of circulating chromatin fragments.Type: ApplicationFiled: January 24, 2011Publication date: November 29, 2012Inventors: Indraneel Mittra, Rekha Mannemcherril Ramesan, Chandra Prakash Sharma, Gopichettipalayam Subbaratnam Vaneshwar, Kavita Anirban Pal
-
Publication number: 20120302499Abstract: Methods for sterilizing and decellularizing extracellular matrix materials are disclosed. Extracellular matrix compositions produced using the disclosed methods are also disclosed.Type: ApplicationFiled: May 24, 2012Publication date: November 29, 2012Inventor: ROBERT G. MATHENY
-
Publication number: 20120294902Abstract: The present invention is directed to peptide amphiphile compounds, compositions and methods of use, wherein nanofiber bundling or epitope aggregation is inhibited. In certain embodiments, the peptide amphiphiles of the present invention have increased solubility and reduced nanofiber bundling. The molecules may be used in pharmaceutical applications, for example for in vivo administration to human patients, by increasing biological activity of the compositions toward neurite outgrowth and nerve regeneration.Type: ApplicationFiled: April 9, 2012Publication date: November 22, 2012Inventors: Samuel I. Stupp, Joshua E. Goldberger, Eric J. Berns
-
Publication number: 20120294903Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to methods of making nanostructures (e.g., nanoparticles, nanofibers), systems for making nanostructures, and the like.Type: ApplicationFiled: April 27, 2012Publication date: November 22, 2012Applicants: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., The Board of Trustees of the Leland Stanford Junior UniversityInventors: Peng Guo, Charles R. Martin, Yaping Zhao, Richard N. Zare
-
Publication number: 20120288553Abstract: The present invention provides a method for controlling toxicity of metallic particles and a low-toxicity composite of metallic nanoparticles and inorganic clay. The metallic nanoparticles are effective in preventing infection and in skinning over, and thus suitable for treating scalds/burns. In the composite, the weight ratio of metallic nanoparticles to inorganic clay preferably ranges 0.1/99.9 to 6.0/94.0 in a size of about 5 to 100 nm. Preferably, the metal is silver and the inorganic clay is nano silicate platelets.Type: ApplicationFiled: July 14, 2012Publication date: November 15, 2012Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Jiang-Jen Lin, Hong-Lin Su, Fu-Chuo Peng, Chia-Yu Chu, Ying-Fang Chiu, Pei-Ru Li, Hsi-Tai Sun
-
Publication number: 20120288533Abstract: The present invention provides protein (or peptide)-polysaccharide (or oligosaccharide) conjugates (PPC) as nanocapsular vehicles for nanoencapsulation of biologically active compounds, particularly nutraceuticals. The PPCs efficiently protect both hydrophobic (i.e., water insoluble) and hydrophilic (i.e., water soluble) nutraceuticals, to provide a composition which, when added to a beverage, disperses so as to provide a clear or transparent solution. In some embodiments, the PPCs are Maillard reaction based PPCs. Advantageously, the conjugates of the present invention protect the nutraceuticals from degradation, both during shelf life and upon gastric digestion.Type: ApplicationFiled: March 1, 2012Publication date: November 15, 2012Applicant: Technion Research and Development Foundation Ltd.Inventor: Yoav D. Livney
-
Publication number: 20120288535Abstract: This document provides methods and materials related to rare earth particles such as rare earth nanorods (e.g., inorganic lanthanide hydroxide nanorods). For example, rare earth (e.g., lanthanide) particles such as europium hydroxide nanorods, methods and materials for making rare earth particles (e.g., europium hydroxide nanorods), and methods and materials for using rare earth particles (e.g., europium hydroxide nanorods) as an imaging agent and/or to promote angiogenesis are provided.Type: ApplicationFiled: April 9, 2012Publication date: November 15, 2012Applicant: Mayo Foundation for Medical Education and ResearchInventors: Chittaranjan Patra, Priyabrata Mukherjee, Resham Bhattacharya, Debabrata Mukhopadhyay, Nicholas E. Vlahakis
-
Publication number: 20120282176Abstract: Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC50-value of the binding pair that binds to an internalizing cell surface receptor determined at pH 5.5 is higher than the EC50-value of the same binding pair determined at pH 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.Type: ApplicationFiled: April 18, 2012Publication date: November 8, 2012Applicant: Roche Glycart AGInventors: Bernd Bohrmann, Per-Ola Freskgard, Adrian Hugenmatter, Erhard Kopetzki, Ekkehard Moessner, Jens Niewoehner, Hadassah Sumum Sade, Pablo Umaña
-
Publication number: 20120282314Abstract: Depigmenting compositions having improved effectiveness in the dermatological or cosmetic treatment of pigmentation contain, in a physiologically acceptable medium, at least one compound selected from among rucinol and salts thereof, and at least one retinoid; such compositions are also useful in the prevention and/or dermatological treatment of skin hyperpigmentation, and also for the cosmetic treatment of photoinduced or chronological aging of the skin or of the skin appendages.Type: ApplicationFiled: July 17, 2012Publication date: November 8, 2012Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Isabelle PELISSON, Itaru SUZIKI
-
Publication number: 20120282343Abstract: The present invention provides nanoparticle compositions comprising a cationic biopolymer and at least one biologically active substance, pharmaceutical compositions comprising such nanoparticles and methods for the oral administration of biologically active molecules which are susceptible to degradation in the gastro-intestinal tract using nanoparticle. The present invention further provides compositions and methods for the oral administration of gene therapy.Type: ApplicationFiled: May 7, 2012Publication date: November 8, 2012Applicant: Johns Hopkins UniversityInventors: Kam W. Leong, Grace Okoli, Gonzalo Hortelano
-
Publication number: 20120283213Abstract: The present invention relates to the modification of hyaluronic acid (HA) with aryl/alkyl succinic anhydrides (ASA) to produce aryl/alkyl succinic anhydride HA derivatives, to the derivatives as such, and to their applications and uses, particularly in the cosmetic and biomedical industries. The ASA-HA derivatives are expected to have interesting properties that can be used for advanced formulation (bind stronger to the skin compared to non-modified HA), possibly also in delivery systems for actives or drugs by encapsulation (nano/micro capsules) or formation of nano/micro spheres. Further, the low MW ASA-HA derivatives are expected to penetrate the skin more efficiently than non-modified HA of the same MW.Type: ApplicationFiled: July 20, 2012Publication date: November 8, 2012Applicant: NOVOZYMES BIOPOLYMER A/SInventors: Kristoffer Tømmeraas, Corinne Eenschooten
-
Publication number: 20120282324Abstract: The present invention provides methods of promoting the revascularization and/or reenervation of central nervous system lesions using an in-situ crosslinkable hydrogel. The present invention also provides methods of treating a spinal cord injury by topically delivering to the spinal cord injury site a vehicle comprising a neurotrophic factor and/or anti-inflammatory agent. Also provided are methods of treating a spinal cord injury by topically administering or delivering a hydrogel to the injury site.Type: ApplicationFiled: April 13, 2012Publication date: November 8, 2012Inventors: Jin Xing, Wen Xuejun, Vibhor Krishna, Ning Zhang
-
POLYMER COATED FERRITE FINE PARTICLES AND METHOD FOR PREPARING POLYMER COATED FERRITE FINE PARTICLES
Publication number: 20120269737Abstract: [Object] To provide a polymer coated ferrite fine particles being possible to control a particle size uniformly while having high aqueous dispersibility and preferred biomolecule immobilization ability and an easy method for preparing the same. [Means Addressing Object] In an aqueous solvent, iron ion is protected by chelating polyacrylic acid and then alkaline is added. Thereafter, a reaction system is heated under pressurized condition to produce simultaneous precipitation of the ferrite fine particles and coating thereof. As the result, the polymer coated ferrite fine particles having uniform particle size may be prepared in one step with excellent reproducibility. The polymer coated ferrite fine particles of the present invention has high water dispersibility and has preferred biomolecule immobilization performance by carboxyl groups coming from the polyacrylic acid.Type: ApplicationFiled: October 28, 2010Publication date: October 25, 2012Applicant: TOKYO INSTITUTE OF TECHNOLOGYInventors: Hiroshi Handa, Mamoru Hatakeyama, Satoshi Sakamoto, Hiroshi Kishi -
Publication number: 20120269888Abstract: The invention is directed to a barrier composition, to a vehicle comprising said barrier composition, to a layer comprising said barrier composition, to a foodstuff comprising said vehicle or layer, to a pharmaceutical or nutraceutical composition comprising said vehicle or layer, to a method for protecting one or more active ingredients, and to the use of said barrier composition. The barrier composition of the invention comprises: a hydrophobic organic phase; and 0.1-75 vol. %, based on the total volume of the barrier composition, of biodegradable solid plate-like particles.Type: ApplicationFiled: October 20, 2010Publication date: October 25, 2012Applicant: Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNOInventors: Jan Matthijs Jetten, Jacobus Eversdijk, Kjeld Jacobus Cornelis van Bommel, Johannes Wilhelmus Timmermans, Aafke Tessa ten Cate, Theodoor Maximiliaan Slaghek
-
Publication number: 20120264802Abstract: The present invention relates to photosensitizer compounds based on functionalized fullerenes useful in targeted photodynamic therapy (PDT), and methods of use thereof.Type: ApplicationFiled: May 31, 2012Publication date: October 18, 2012Applicants: Lynntech, Inc., The General Hospital CorporationInventors: Tim Wharton, Hariprasad Gali, Michael R. Hamblin
-
Publication number: 20120263764Abstract: Provided are methods for treating inflammatory neurodegenerative diseases (e.g., multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, Huntington's disease, migraine, cerebral amyloid angiopathy, inflammatory neurodegenerative condition associated with AIDS, age-related cognitive decline; mild cognitive impairment and prion diseases in a mammal), or at least one symptom thereof in a subject by administering a therapeutic composition comprising at least one electrokinetically-altered fluids (e.g., electrokinetically-generated oxygen-enriched fluids) of the present invention. Particular aspects provide methods for inhibiting and/or modulating the function and/or activity of effector T-cells, and/or for cell-based tolerogenic therapy (e.g., by modulating development and/or function and/or activity of TREG cells and/or dendritic cells (DCs) and/or TH17 cells (e.g., ROR?t+ TH17 cells).Type: ApplicationFiled: April 13, 2012Publication date: October 18, 2012Applicant: Revalesio CorporationInventor: Richard L. WATSON
-
Publication number: 20120263793Abstract: The invention relates generally to the field of plasmonics, and more specifically, in one embodiment, it relates to fabricating elements in whole or in part using one or more self-assembling elements comprised of purified, synthetic and or recombinant protein molecule elements and or their accessory elements, and in particular, composed of at least one or more Clathrin and or Coatomer I/II protein molecules, forming one or more self-assembling structure and framework elements of one or more molecular weights, dimensions, geometries, symmetries, configurations and combinations. In another aspect, the invention relates to a method using one or more nanoscale metal surface elements that, when one or more appropriate types or forms of energies are applied to one or more types of metal elements, emit one or more preferred types or forms of surface-plasmon-enhanced electromagnetic radiation and energy.Type: ApplicationFiled: April 10, 2012Publication date: October 18, 2012Inventor: Franco Vitaliano
-
Publication number: 20120251437Abstract: The present invention relates to a process for the polyol-type synthesis of nanoparticulate magnetite starting from mixtures of Fe0 and FelIII in the presence of a mineral acid. The magnetite particles obtainable from the process have uniform size characteristics and have even presented higher SAR (Specific Absorption Rate) values than those of magnetosomes.Type: ApplicationFiled: December 15, 2010Publication date: October 4, 2012Applicant: COLOROBBIA ITALIA S.P.A.Inventors: Marco Bitossi, Giovanni Baldi, Franco Innocenti
-
Publication number: 20120251450Abstract: Of the many compositions and methods provided herein, one composition includes a nanoparticle having a first oxide of a first metal and a dopant that includes an ion or an atom of a second metal. A method includes a method comprising providing a plurality of nanoparticles comprising a first oxide of a first metal and a dopant that comprises an ion or an atom of a second metal; providing a diseased cell and a healthy cell; contacting the diseased cell and the healthy cell with the nanoparticle; and allowing the nanoparticle to preferentially associate with the diseased cell.Type: ApplicationFiled: April 4, 2011Publication date: October 4, 2012Inventors: Alex Punnoose, Denise Wingett
-
Publication number: 20120251521Abstract: The present invention is a solution or colloid of fullerene, SWNTs, or graphene in cyclic terpenes, lactones, terpene-alcohol, fatty-acid alcohols, and lactones following ultrasonication and ultracentrifugation processing, for oil-energy, biological, electrical-thermal applications. The compositions are useful as fuel/oil/grease/gels (synthetic included), oil/fuel/additives/propellants, identification dyes, and heat-transfer fluids. Other functions are phase-change fluids for solar energy power plants, antifreeze, electronic dyes, electrolytic fluid/solvent, electrically-thermally conductive material for electrochemical, dielectric, filler/adhesive for semiconductor, eletro-optical, and liquid crystal substrates/coatings for touch sensitive transmissive or reflective displays. When combined with gelatin the formulations can function as dichroic-optical coatings for thin-films/waveguides/holograms.Type: ApplicationFiled: April 2, 2011Publication date: October 4, 2012Inventors: Bertha Rostro, Mehdie Kohanloo
-
Publication number: 20120244134Abstract: The present invention provides a process for preparing an aqueous dispersion containing a high concentration of nano/submicron, hydrophobic, functional compounds. The process is carried out by using a complex stabilizer having an HLB value of about 10 to about 17, comprising lecithin and at least one non-phospholipid selected from polysorbate, sucrose ester, and polyglycerol fatty acid ester; selecting a specific weight ratio of the hydrophobic functional compounds and the stabilizer; and using homogenization technique, media milling technique, and/or centrifugal technique. The aqueous dispersion containing a high concentration of nano/submicron, hydrophobic, functional compound produced by the process of the invention has stable dispersibility and improved bioavailability, and can be applied to the fields of foods and pharmaceuticals.Type: ApplicationFiled: July 19, 2011Publication date: September 27, 2012Inventors: Ru-Yin CHEN, Chung-Jen CHEN, Yi-Jie TSAI, Jia-Jiu WU, Chih-Ping HUANG, Chung-Liang CHU